NCT03925324: A reported trial by Medstar Health Research Institute
This trial has reported on time, in line with the regulations.
Full data
| Full entry on ClinicalTrials.gov | NCT03925324 |
|---|---|
| Title | A Randomized, Double-Blind, Placebo-Controlled Phase IIa Study of the Safety and Efficacy of Intravenous Delivery of Allogeneic Mesenchymal Stem Cells in Cardiomyopathy Patients and Implanted Left Ventricular Assist Device |
| Results Status | Reported |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | May 3, 2019 |
| Completion date | Aug. 16, 2021 |
| Required reporting date | Aug. 16, 2022, midnight |
| Actual reporting date | Jan. 3, 2022 |
| Date last checked at ClinicalTrials.gov | Dec. 5, 2025 |
| Days late | None |